".........The study compared aortic flow haemodynamics in five patients who had received a DurAVRTM valve against other transcatheter aortic valve implants (TAVI) and patients who had surgical aortic valve replacement (SAVR). The study results demonstrated the novel leaflet design of DurAVRTM THV restored ascending aortic flow haemodynamics, whereas SAVR and other TAVI valves did not demonstrate the same physiological advantage."
I can't get over this statement in bold in the quarterly . We are better than the gold standard of SAVR. Imagine that
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-26
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.98 |
Change
-0.140(2.29%) |
Mkt cap ! $92.99M | |||
| Open | High | Low | Value | Volume |
| $6.01 | $6.08 | $5.95 | $28.28K | 4.712K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $5.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.07 | 2710 | 2 |
View Market Depth
| Last trade - 13.16pm 26/06/2025 (20 minute delay) ? |
| AVR (ASX) Chart |